175 related articles for article (PubMed ID: 18803534)
1. Prostate cancer and prostate-specific antigen testing in New South Wales.
Smith DP; Supramaniam R; Marshall VR; Armstrong BK
Med J Aust; 2008 Sep; 189(6):315-8. PubMed ID: 18803534
[TBL] [Abstract][Full Text] [Related]
2. Prostate-specific antigen testing in Australia and association with prostate cancer incidence in New South Wales.
Smith DP; Armstrong BK
Med J Aust; 1998 Jul; 169(1):17-20. PubMed ID: 9695696
[TBL] [Abstract][Full Text] [Related]
3. Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study.
Collin SM; Martin RM; Metcalfe C; Gunnell D; Albertsen PC; Neal D; Hamdy F; Stephens P; Lane JA; Moore R; Donovan J
Lancet Oncol; 2008 May; 9(5):445-52. PubMed ID: 18424233
[TBL] [Abstract][Full Text] [Related]
4. Changes in prostate cancer incidence, mortality and survival in relation to prostate specific antigen testing in New South Wales, Australia.
Luo Q; Yu XQ; Kahn C; Egger S; Patel MI; Grogan PB; Caruana M; Canfell K; Smith DP; O'Connell DL
Cancer Epidemiol; 2022 Jun; 78():102159. PubMed ID: 35447540
[TBL] [Abstract][Full Text] [Related]
5. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends.
Etzioni R; Penson DF; Legler JM; di Tommaso D; Boer R; Gann PH; Feuer EJ
J Natl Cancer Inst; 2002 Jul; 94(13):981-90. PubMed ID: 12096083
[TBL] [Abstract][Full Text] [Related]
6. Prostate cancer in Western Australia: trends in incidence and mortality from 1985 to 1996.
Threlfall TJ; English DR; Rouse IL
Med J Aust; 1998 Jul; 169(1):21-4. PubMed ID: 9695697
[TBL] [Abstract][Full Text] [Related]
7. Trends in Prostate Specific Antigen (PSA) testing and prostate cancer incidence and mortality in Australia: A critical analysis.
Pathirana T; Sequeira R; Del Mar C; Dickinson JA; Armstrong BK; Bell KJL; Glasziou P
Cancer Epidemiol; 2022 Apr; 77():102093. PubMed ID: 35026706
[TBL] [Abstract][Full Text] [Related]
8. Prostate-specific antigen testing for prostate cancer: Depleting a limited pool of susceptible individuals?
Valberg M; Grotmol T; Tretli S; Veierød MB; Moger TA; Devesa SS; Aalen OO
Eur J Epidemiol; 2017 Jun; 32(6):511-520. PubMed ID: 27431530
[TBL] [Abstract][Full Text] [Related]
9. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria.
Bartsch G; Horninger W; Klocker H; Reissigl A; Oberaigner W; Schönitzer D; Severi G; Robertson C; Boyle P;
Urology; 2001 Sep; 58(3):417-24. PubMed ID: 11549491
[TBL] [Abstract][Full Text] [Related]
10. Prostate cancer and prostate-specific antigen (PSA) screening in Austria.
Vutuc C; Schernhammer ES; Haidinger G; Waldhör T
Wien Klin Wochenschr; 2005 Jul; 117(13-14):457-61. PubMed ID: 16091872
[TBL] [Abstract][Full Text] [Related]
11. The role of prostate-specific antigen (PSA) testing patterns in the recent prostate cancer incidence decline in the United States.
Legler JM; Feuer EJ; Potosky AL; Merrill RM; Kramer BS
Cancer Causes Control; 1998 Oct; 9(5):519-27. PubMed ID: 9934717
[TBL] [Abstract][Full Text] [Related]
12. Urban-rural differences in prostate cancer mortality, radical prostatectomy and prostate-specific antigen testing in Australia.
Coory MD; Baade PD
Med J Aust; 2005 Feb; 182(3):112-5. PubMed ID: 15698354
[TBL] [Abstract][Full Text] [Related]
13. Screening for prostate cancer: updated experience from the Tyrol study.
Horninger W; Berger A; Pelzer A; Klocker H; Oberaigner W; Schönitzer D; Severi G; Robertson C; Boyle P; Bartsch G
Can J Urol; 2005 Feb; 12 Suppl 1():7-13; discussion 92-3. PubMed ID: 15780158
[TBL] [Abstract][Full Text] [Related]
14. Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection.
Ross KS; Carter HB; Pearson JD; Guess HA
JAMA; 2000 Sep; 284(11):1399-405. PubMed ID: 10989402
[TBL] [Abstract][Full Text] [Related]
15. Trends in prostate specific antigen testing in Ireland: lessons from a country without guidelines.
Drummond FJ; Carsin AE; Sharp L; Comber H
Ir J Med Sci; 2010 Mar; 179(1):43-9. PubMed ID: 19562407
[TBL] [Abstract][Full Text] [Related]
16. PSA testing in Austria: induced morbidity and saved mortality.
Vutuc C; Waldhoer T; Lunglmayr G; Hoeltl W; Haidinger G
Eur J Cancer Prev; 2009 Sep; 18(5):377-80. PubMed ID: 19512934
[TBL] [Abstract][Full Text] [Related]
17. Annual Report to the Nation on the Status of Cancer, part II: Recent changes in prostate cancer trends and disease characteristics.
Negoita S; Feuer EJ; Mariotto A; Cronin KA; Petkov VI; Hussey SK; Benard V; Henley SJ; Anderson RN; Fedewa S; Sherman RL; Kohler BA; Dearmon BJ; Lake AJ; Ma J; Richardson LC; Jemal A; Penberthy L
Cancer; 2018 Jul; 124(13):2801-2814. PubMed ID: 29786851
[TBL] [Abstract][Full Text] [Related]
18. Discrepancies between guidelines and clinical practice regarding prostate-specific antigen testing.
Hamoen EH; Reukers DF; Numans ME; Barentsz JO; Witjes JA; Rovers MM
Fam Pract; 2013 Dec; 30(6):648-54. PubMed ID: 24107269
[TBL] [Abstract][Full Text] [Related]
19. Past, Current, and Future Incidence Rates and Burden of Metastatic Prostate Cancer in the United States.
Kelly SP; Anderson WF; Rosenberg PS; Cook MB
Eur Urol Focus; 2018 Jan; 4(1):121-127. PubMed ID: 29162421
[TBL] [Abstract][Full Text] [Related]
20. An examination of prostate cancer trends in Australia, England, Canada and USA: Is the Australian death rate too high?
Feletto E; Bang A; Cole-Clark D; Chalasani V; Rasiah K; Smith DP
World J Urol; 2015 Nov; 33(11):1677-87. PubMed ID: 25698456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
